Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Macy's Inc (M) Price & Performance

BioNano Genomics IncTrade
Macy's IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Macy's Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Macy's Inc trades at $23.18 (market cap $6.11B). The key difference: Macy's Inc is far larger — about 462.9× BioNano Genomics Inc's market cap, and Macy's Inc pays a 3.3% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOM
Market Cap
$13.20M$6.11B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$25.96
52-Week Low
$1.09$11.90
Enterprise Value
$15.81M$9.92B
Dividend Yield
3.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Macy's Inc

Macy's (M) trades at $22.78, up 0.62% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 9.41 and P/S of 0.28, alongside improving cash flow and a recent earnings beat streak. The 'Bold New Chapter' strategy is driving operational improvements, with Berkshire Hathaway's new stake in Q1 2026 signaling institutional confidence.

The outlook is cautiously optimistic, supported by low valuation and strategic initiatives, but risks include margin pressure from retail sector headwinds and execution challenges in the turnaround plan. Analyst consensus is mixed, with a $24.83 price target suggesting modest upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M